Evernorth is offering the weight loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide) to patients at a monthly cost of no more than $200, which will also count toward patients’ deductibles. Patients can save as much as $3,600 per year compared with direct-to-consumer manufacturer programs, Evernorth said in a news release .

Additionally, the PBM said that the prior authorization processes will be simplified and automated for faster access, and patients will be able to access the medications through a network of local retail pharmacies or through home delivery through Evernorth’s EnGuide Pharmacy.

Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications, according to Evernorth.

Evernorth executives say they are able to offer prod

See Full Page